It was first approved in 2022 by the FDA for the treatment of adults with type II diabetes mellitus (T2DM)
These studies suggest GLP-1 drugs may one day, after robust clinical trials, be used by many more people than they are today, says Professor Marcin Chwistek, Chief of Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center
Kevin M
All concentrations, all doses, one table *Exceeds 100 units, requires split injection across two syringes This table eliminates the need for separate charts
Product Line We implement strict management and control throughout the entire process from research and development, procurement of raw materials, production and input, to final product testing, packaging, delivery, and transportation
Overall, the efficacy of these drugs ranges from 5 percent to 10 percent average weight loss and many are limited by their less-tolerated side effects. Whats coming down the pipeline